Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 43% Improvement Relative Risk Ventilation 33% Lien et al. Colchicine for COVID-19 META ANALYSIS Favors colchicine Favors control
Repurposing Colchicine in Treating Patients with COVID-19: A Systematic Review and Meta-Analysis
Lien et al., Life, doi:10.3390/life11080864
Lien et al., Repurposing Colchicine in Treating Patients with COVID-19: A Systematic Review and Meta-Analysis, Life, doi:10.3390/life11080864
Aug 2021   Source   PDF  
  All Studies   Meta
Meta analysis of 11 colchicine studies showing significantly lower mortality with treatment.
Currently there are 46 colchicine studies and meta analysis shows:
Mortality35% lower [23‑45%]
Ventilation29% lower [-15‑56%]
ICU admission25% lower [3‑43%]
Hospitalization18% lower [9‑26%]
Cases9% more [-6‑27%]
risk of death, 43.0% lower, OR 0.57, p = 0.008, RR approximated with OR.
risk of mechanical ventilation, 33.0% lower, OR 0.67, p = 0.15, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Lien et al., 23 Aug 2021, peer-reviewed, 12 authors.
Contact: (corresponding author),,,,,,,,,,,
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperColchicineAll
Abstract: life Systematic Review Repurposing Colchicine in Treating Patients with COVID-19: A Systematic Review and Meta-Analysis Chi-Hone Lien 1,† , Ming-Dar Lee 1,† , Shun-Long Weng 1,2 , Chao-Hsu Lin 1,3 , Lawrence Yu-Min Liu 1,2 , Yu-Lin Tai 1 , Wei-Te Lei 1,4 , Jui-Ming Liu 5 , Ya-Ning Huang 6 , Hsin Chi 2,6 , Nan-Chang Chiu 2,6 and Chien-Yu Lin 1,2, * 1 2 3 4 5 6   * † Hsinchu MacKay Memorial Hospital, Hsinchu 30071, Taiwan; (C.-H.L.); (M.-D.L.); (S.-L.W.); (C.-H.L.); (L.Y.-M.L.); (Y.-L.T.); (W.-T.L.) Department of Medicine, MacKay Medicine College, New Taipei City 25160, Taiwan; (H.C.); (N.-C.C.) Department of Biological Science and Technology, National Chiao-Tung University, Hsinchu 30010, Taiwan Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan Department of Urology, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan 33004, Taiwan; Department of Pediatrics, MacKay Children’s Hospital, Taipei 10449, Taiwan; Correspondence:; Tel.: +886-3-6119595 These authors contributed equally to the work. Citation: Lien, C.-H.; Lee, M.-D.; Weng, S.-L.; Lin, C.-H.; Liu, L.Y.-M.; Tai, Y.-L.; Lei, W.-T.; Liu, J.-M.; Huang, Y.-N.; Chi, H.; et al. Repurposing Colchicine in Treating Patients with COVID-19: A Systematic Review and Meta-Analysis. Life 2021, 11, 864. Academic Editors: Dimitrios Paraskevis, Sotirios Tsiodras and Maria Yavropoulou Received: 30 June 2021 Accepted: 19 August 2021 Published: 23 August 2021 Publisher’s Note: MDPI stays neutral Abstract: Coronavirus disease 2019 (COVID-19) had caused huge health losses worldwide. Several drugs had been applied to treat patients with COVID-19, and repurposing colchicine had been proposed for its anti-inflammatory properties via several pathways. In this systematic review, we evaluated the effects of colchicine treatment. From inception to May 31, 2021, databases, including PubMed, EMbase, medRxiv, and Research Square were searched, and 11 studies were enrolled. A total of 17,205 COVID-19 patients with male predominance (62.9%) were analyzed. Patients with colchicine treatment had a significantly lower risk of mortality (odds ratio (OR): 0.57, 95% confidence interval (CI): 0.38–0.87, I2 : 72%; p < 0.01) and a non-significantly lower rate of mechanical ventilation (OR: 0.67, 95%CI: 0.39–1.15). The side effects were mild and not significantly different (OR: 2.03, 95%CI: 0.51–8.09). Subgroup analysis with randomized controlled trials showed no statistically significant difference in the mortality (OR: 0.80, 95%CI: 0.44–1.46, I2 : 33%; p = 0.22). In conclusion, our meta-analysis found that colchicine treatment was associated with a significantly lower risk of mortality in patients with COVID-19. However, this benefit was not observed in the subgroup analysis of randomized controlled trials. Further randomized controlled studies are required to confirm the potential benefits of colchicine treatment. Keywords: COVID-19; novel coronavirus; SARS-CoV-2; colchicine; immunomodulation with regard to jurisdictional claims in published maps and institutional affiliations. Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop